Search company, investor...

Cordio

cordio-med.com

Founded Year

2013

Stage

Series A | Alive

Total Raised

$18M

Last Raised

$18M | 10 mos ago

About Cordio

Cordio develops a mobile device that senses fluid accumulation related to CHF (Congestive Heart Failure) and alerts prior to hospitalization. It offers monitoring, treatment options, and support for a patient’s individual needs. The company was founded in 2013 and is based in Or Yehuda, Israel.

Headquarters Location

6 Yehonatan Netanyahu Street

Or Yehuda, 6037604,

Israel

+972-3-5467159

Missing: Cordio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cordio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cordio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cordio is included in 4 Expert Collections, including Telehealth.

T

Telehealth

2,854 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

M

Medical Devices

197 items

Companies that have publicly disclosed receipt of Breakthrough Device Designation from the FDA. Companies may be presented multiple times (each entry for a distinct BDD). Companies tagged as #FDABreakthroughDeviceDesignation

H

Health Monitoring & Diagnostics

988 items

Companies offering smartphone-based health monitoring & diagnostic solutions (using native components of the smartphone, e.g. camera, microphone, accelerometer, gyroscope, etc.). Companies tagged as #SmartphoneBasedDiagnostics

H

Health IT

8,881 items

Cordio Patents

Cordio has filed 1 patent.

The 3 most popular patent topics include:

  • Artificial intelligence
  • Artificial neural networks
  • Classification algorithms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/3/2020

11/1/2022

Medical diagnosis, Plant anatomy, Medical terminology, Acoustics, Respiratory physiology

Grant

Application Date

3/3/2020

Grant Date

11/1/2022

Title

Related Topics

Medical diagnosis, Plant anatomy, Medical terminology, Acoustics, Respiratory physiology

Status

Grant

Latest Cordio News

Smartphone Tech That Listens Out For Heart Failure

Nov 24, 2022

Algorithm diagnoses condition from six sentences a day Voice technology can now detect early signs of heart problems in cardiac patients, weeks before they’re even aware of any symptoms. All they need to do is record themselves on a smartphone for 45 seconds a day. Then a super-sensitive algorithm “listens out” for problems. The technology, developed by Israel-based Cordio Medical , is designed for patients suffering congestive heart failure, when fluid builds up within the heart and causes it to pump inefficiently. Cordio’s voice app, HearO, has patients recite sentences into it daily, and uses low level speech processing to look at very small changes in the lungs and see if there’s a problem. Courtesy They will already have been diagnosed with the chronic condition and will be taking medication to ease pressure on their hearts. But they won’t be aware of excess fluid gathering in their heart and lungs until it’s too late, and they’re already suffering symptoms of a relapse. Cordio’s voice app, called HearO, can pick up on tiny changes up to 18 days before they start feeling unwell, according to recent tests on patients in Israel. That gives their doctors the chance to double the dose of diuretics – medication that lowers blood pressure – for a few days and avoid the trauma of a stay in the hospital. “We’re probably one of the first companies in the world using speech to actually detect clinical conditions in humans,” says Tamir Tal, the company’s CEO. “Speech carries a lot of personal information about us. When you talk to your mom just one sentence is enough for her to know how you feel. “We’re using speech to give the physician something they can objectively use to determine a patient’s actual medical condition.” The human heart, surrounded by lungs. Deposit Photos A build-up of fluid in the lungs is the best sign that a patient is experiencing undiagnosed heart problems, but measuring it is something that eluded modern medical science, until now. It doesn’t show up on any test or scan. Attempts to track it by measuring a patient’s pulse, breathing and weight throw up too many false positives. Hi-tech wearable devices have had some success, but rely too heavily on patient compliance, says Tal. And monitors that are surgically inserted into the heart provide accurate information but are invasive, expensive and unpopular. But getting a patient to recite six sentences a day into their smartphone is easy, effective and accurate. That daily voice file is enough for the algorithm to know if something is amiss. Our lungs push air through the larynx and are the place where the whole speech process begins, so any irregularities there will affect the way we speak, even if we can’t actually hear it. “What we are doing is called low level speech processing, looking at very, very small changes in the lungs,” says Tal. Sign up for our free weekly newsletter Doctors can check their patients’ daily voice files. Courtesy “It’s like the sensor in a car’s engine that switches on a light on the dashboard if it starts filling with surplus fluid.” Patients recite their sentences daily. One example in English is “Emma bought a nice cup of tea”, but the system caters for half a dozen languages and can readily be adapted for more. Prof Ilan Shallom, who used to work at AudioCodes, one of the largest speech processing companies in the world, developed the real-time speech and voice analysis that detects early build-up of fluids. His work allows HearO to listen out for the variations in sound from the vocal tract that are far too subtle for the human ear to distinguish. Siri and Alexa analyze and understand human language but HearO is a more sophisticated kind of voice technology. Patients record a baseline voice sample when they’re in good health, and the algorithm compares that with the daily sound file they send from their device. A recent study among 180 patients at 10 medical centers in Israel found the system identified heart failure an average of 18 days before it occurred, based on that daily voice sample. It made a correct diagnosis in 82 per cent of cases, compared with only 10 to 20 per cent achieved by monitoring a patient’s weight. HearO is aimed at patients who would have died 20 years ago from a heart attack or other cardiac condition but who are routinely saved today using minimally invasive techniques. Their heart has, nonetheless, suffered a trauma, and is not functioning the way it should. HearO is aimed at patients who would have died 20 years ago from a heart attack or other cardiac condition but who are routinely saved today. Courtesy Tumisu from Pixabay With a healthy heart, blood remains in a closed loop system. But if the heart is working at reduced capacity, then fluid – plasma, water and blood – can start accumulating in the body and eventually start filling the lungs. It typically takes three weeks to a month before the patient will start feeling symptoms. By then it’s too late and they can already be quite seriously ill. Even if the patient was in the hospital, the best MRI machines in the world can’t detect or image fluid, says Tal. “Hence, the reason there is no gold standard in heart failure. Nobody knows when somebody is deteriorating only the physician caring, clinical examination with his status. “There’s currently no examination that can tell you that is happening. Doesn’t matter, another blood test, not an imaging device, absolutely nothing. “People don’t like to use medical devices designed to be used at home. They’re mainly designed for clinical efficacy, rather than the user’s happiness. But people are very happy to use their iPhone or Android.” HearO will undergo two patient trials in Israel next year and has approval to be marketed early in 2023 in Spain, UK and Germany. Subscribe to NoCamels weekly newsletter and get our top stories

Cordio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cordio Rank

Cordio Frequently Asked Questions (FAQ)

  • When was Cordio founded?

    Cordio was founded in 2013.

  • Where is Cordio's headquarters?

    Cordio's headquarters is located at 6 Yehonatan Netanyahu Street, Or Yehuda.

  • What is Cordio's latest funding round?

    Cordio's latest funding round is Series A.

  • How much did Cordio raise?

    Cordio raised a total of $18M.

  • Who are the investors of Cordio?

    Investors of Cordio include Peregrine Ventures, Ceros Capital Markets, BIRD Foundation, Bayer G4A, PlayBeyondBio and 3 more.

  • Who are Cordio's competitors?

    Competitors of Cordio include Donisi Health.

Compare Cordio to Competitors

B
BioBeat

BioBeat is a system that facilitates non-invasive accurate medical-grade monitoring of vital signs and other medically relevant parameters. The company's system can monitor a variety of medical issues for stationary and active patients at home. BioBeat was founded in 2014 and is headquartered in Petach-Tikva, Israel.

S
Sensible Medical Innovations

Sensible Medical Innovation develops a sensing and monitoring technology that provides actionable and accurate data for guiding the management and treatment of several chronic medical conditions.

N
Neteera Technologies

Neteera developed a sensing technology comprised of a combination of a CMOS based sub-THz sensor and proprietary software and algorithms. The technology is used for signal processing and data interpretation (one example is continuous, remote, and contact-free vital sign and well-being monitoring of driver and vehicle occupants).

Acorai Logo
Acorai

Acorai develops a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM) to help reduce hospitalizations and readmissions. The Acorai Heart Monitor can monitor intracardiac pressures non-invasively through a machine learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. The company was founded in 2019 and is based in Helsingborg, Sweden.

D
Donisi Health

Donisi Health develops a clinically validated, contact-free device designed for both cardiac and respiratory assessment. The company aids patients with congestive heart failure (CHF) and other chronic cardiopulmonary diseases by monitoring patient's health. It offers services such as remote health monitoring and teleconsultation services. It caters to old-age individuals. The company was founded in 2015 and is based in Israel, Tel Aviv.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.